Cancer Drugs Cost Patients And Payers 189% More In Hospitals vs. Physician Offices – IMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Differences in covered costs were greatest for Avastin, Lemtrada, Perjeta and Rituxan, among 10 commonly prescribed drugs studied, IMS found. Patient cost sharing was an average $134 higher per dose in hospitals.
You may also be interested in...
BIO Targets 340B Hospital Acquisitions Of Oncology Practices In Study
In an effort to support its claim that the 340B drug discount program is being used by hospitals to generate profits, the Biotechnology Industry Organization released a study finding use of 340B drugs at physician-based oncology practices grew significantly after they were acquired by hospitals.
340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.